Today's Date: March 28, 2024
In 23rd Annual Sexual Assault Awareness Month Campaign, NSVRC Calls for Building Connected Communities to Prevent Sexual Violenc   •   Boston Children’s Hospital and NRG Energy celebrate $1 million milestone, thanks to the Choose to Give program   •   ComPsych Corporation Announces 2023 Health at Work Award Winners   •   Black & Veatch Distributed Infrastructure Business Awarded Highest OSHA Star Recognition   •   Guaranteed Rate Welcomes New Atlanta Branch Manager, Carlos Mata   •   /R E M I N D E R -- Travelling for Easter? The Canada Border Services Agency gives tips for a smooth trip/   •   THE ST. JAMES AND TPH ACADEMY PARTNER TO LAUNCH PREMIER ACADEMIC AND SPORTS PERFORMANCE ACADEMY SERVING THE GREATER WASHINGTON R   •   Modern Health & Naomi Osaka’s Hana Kuma Launch Mental Health Focused Video Podcast Series “Can’t Wait To H   •   BMO Recognized for Gender Equity by Report on Business' Women Lead Here List 2024   •   Children's Hospital of Philadelphia's Richard D. Wood Jr. Center for Fetal Diagnosis and Treatment Earns Two Press Ganey Awards   •   Green Boom Expands Product Line to The Home Depot   •   Leading In-Home Care Franchise Looks to Expand in La Crosse   •   Yamaha Motor Signs Technical Partnership with Lola Cars for Development and Supply of Powertrains for Formula E   •   Morningstar Publishes Fourth Annual Corporate Sustainability Report   •   Jack Link’s® Unveils a Sweet Collaboration with Dr Pepper® That Brings Two Classic Tastes Together   •   Tractor Supply Opens Applications for Second Annual Open Buying Days Event   •   Lutheran Senior Services and Diakon Enter Into Senior Living Agreement   •   From Tee to Triumph: Teen Entrepreneur and Golf Sensation Hosts First Annual Autism Awareness Golf Tournament   •   Stamp showcasing maamoul commemorates Islamic festivals of Eid al-Fitr and Eid al-Adha   •   ElementalTV and Spanglish Movies Partner to Accelerate US Hispanic Market Activations in CTV Advertising: 'Spanglish Audiences'
Bookmark and Share

Phase 2b Clinical Trial Results for TYK2 Inhibitor Presented at American Academy of Dermatology Annual Meeting

BOSTON , March 20 /Businesswire/ - Results from the Phase 2b clinical trial of TAK-279 (formerly NDI-034858), a novel allosteric TYK2 inhibitor developed by Nimbus Therapeutics and owned by Takeda (TSE:4502/NYSE:TAK), in patients with moderate-to-severe plaque psoriasis were presented on Saturday, March 18, 2023 at the 2023 American Academy of Dermatology (AAD) Annual Meeting in New Orleans.

The results were presented as part of the Late-Breaking Research session by April Armstrong, M.D., MPH, clinical investigator in the Phase 2b study and Associate Dean and Professor of Dermatology at the University of Southern California.

From Takeda’s press release dated March 18th:

In the Phase 2b study, 259 patients were randomized (1:1:1:1:1 ratio) to receive one of four doses of TAK-279 once-daily, or placebo for 12 weeks. Results showed:

  • A significantly greater proportion of TAK-279 patients achieved PASI 75 (44%, 68%, 67%; 5mg, 15mg, 30mg, respectively) versus placebo (6%; p<0.001), meeting the study’s primary endpoint.
  • A significantly greater proportion of TAK-279 patients achieved PASI 90 (21%, 45%, 46%; 5mg, 15mg, 30mg, respectively) versus placebo (0%; p<0.001), and PASI 100 (10%, 15%, 33%; 5mg, 15mg, 30mg, respectively) versus placebo (0%; p<0.001 at 30mg).
  • A significantly greater proportion of TAK-279 patients achieved Physician Global Assessment (PGA) scores of 0/1 (27%, 49%, 52%; 5mg, 15mg, 30mg, respectively) or 0 (10%, 15%, 33%; 5mg, 15mg, 30mg, respectively) versus placebo (4% [p≤0.001] and 0% [p<0.001 at 30mg], respectively) at 12 weeks. A PGA score of 1 indicates almost clear skin and 0 indicates totally clear skin.
  • There were no statistically significant differences in PASI or PGA response rates seen in the TAK-279 2mg arm (18%, 2%, 10%, 2%; PASI 75, PASI 100, PGA 0/1, PGA 0, respectively) compared to placebo.

“We are thrilled to see this data shared with the scientific community, underscoring this medicine’s potential to address the high unmet need among patients with psoriasis and other immune-mediated diseases,” said Jeb Keiper, M.S., MBA, Chief Executive Officer of Nimbus. “This marks a turning point to the next ‘chapter’ of Nimbus. We have advanced our leading-edge technologies and grown our expertise in small molecule drug development to deliver breakthrough medicines, by design, for the benefit of patients.”

About Nimbus Therapeutics

Nimbus Therapeutics is a clinical-stage, structure-based drug discovery company developing novel small molecule medicines designed to act against well-validated but difficult-to-drug targets implicated in multiple human diseases. Nimbus combines leading-edge computational technologies with a tailored array of machine learning-based predictive modeling approaches. Nimbus’ pipeline includes a clinical-stage HPK1 inhibitor for the treatment of cancer (NCT05128487), as well as a diverse portfolio of preclinical programs focused on cancer, inflammatory and autoimmune conditions and metabolic diseases. Nimbus is headquartered in Boston, MA. To learn more about Nimbus, please visit www.nimbustx.com.


STORY TAGS: Massachusetts, Biotechnology, Pharmaceutical, Health, Clinical Trials, Event, United States, North America,

Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News